Key result
Lifestyle intervention cuts low ABI progression ~57% vs placebo, but metformin increases high ABI progression.
Why the study?
Abnormal ankle-brachial index reflects distinct cardiovascular risks, but the long-term effects of lifestyle and metformin interventions on ABI progression in adults with prediabetes were unclear.
Does lifestyle intervention or metformin prevent progression to abnormal ankle-brachial index in adults with prediabetes?
RCT (n=3,234)
randomized
Does lifestyle intervention or metformin prevent progression to abnormal ankle-brachial index in adults with prediabetes?
In adults with prediabetes, lifestyle modification reduces the risk of developing atherosclerotic low ABI, whereas metformin may increase the risk of medial arterial calcification (high ABI) over 14 years.
Answers are grounded in this paper and cite their sources.
Lifestyle intervention merits priority over metformin in prediabetes to reduce low ABI risk; challenges assumptions of neutral vascular effects for metformin.
Introduction and Objective: Peripheral artery disease is marked by abnormal ankle-brachial index (ABI): low ABI (<0.90) reflects atherosclerotic disease, while high ABI (≥1.30) suggests medial arterial calcification, each with distinct cardiovascular risks. This study evaluated effects of lifestyle and metformin interventions on ABI progression and identified clinical correlates of abnormal ABI development over 14 years in adults with prediabetes. Methods: Among 3,234 Diabetes Prevention Program (DPP) participants randomized to lifestyle intervention, metformin, or placebo, serial ABI measurements were obtained pre-randomization (baseline) and 1, 3, 8, and 14 years after randomization. Multivariable logistic regression identified factors associated with progression from normal at baseline to low or high ABI at year 14. Results: At baseline, mean age was 51 years, 69% were female, and 20% identified as Black or African American. Low ABI prevalence was modest (peak prevalence of 7.5% by year 14), while high ABI prevalence reached 33% by year 14. Randomization to lifestyle intervention was associated with 57% lower odds of progression to low ABI (adjusted OR=0.43, 95% CI 0.24-0.77, p=0.005) relative to placebo; metformin showed no benefit. Randomization to metformin was associated with higher odds of progression to high ABI (adjusted OR=1.35, 95% CI 1.04-1.77, p=0.027) relative to placebo; lifestyle was not significantly associated with high ABI. Older age and higher fasting glucose at baseline were associated with progression to low ABI, while female sex and higher baseline level of hsCRP (mean=0.59 mg/dL) were protective against high ABI. These divergent risk-factor profiles indicate potential distinct pathophysiological mechanisms. Conclusion: Among persons with prediabetes lifestyle modification may reduce the risk of atherosclerotic low ABI while metformin may raise risk of high ABI. Distinct metabolic and inflammatory profiles may underlie progression to low versus high ABI. Disclosure P.S. Garimella: Consultant; Current; Otsuka America Pharmaceutical, Inc.
No takes yet. Share an insight, caveat, or question.
Garimella et al. (2026) conducted an RCT in prediabetes (n=3,234). Lifestyle intervention vs. Placebo was evaluated on Progression from normal at baseline to low ABI at year 14 (OR 0.43, 95% CI 0.24-0.77, p=0.005). Lifestyle intervention reduced the odds of progression to low ABI, whereas metformin increased the odds of progression to high ABI compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: